Trial Profile
A Single Dose Pharmacokinetic Study of LY2605541 in Subjects With Hepatic Impairment
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Insulin peglispro (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Eli Lilly and Company
- 19 Sep 2014 Results presented at the 50th Annual Meeting of the European Association for the Study of Diabetes.
- 17 Jan 2014 Status changed from active, no longer recruiting to completed as reported byClinical trial.gov record.
- 09 Sep 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.